EUCTR2008-000601-11-AT进行中（未招募）不适用
SORATACE: Sorafenib (Nexavar®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a pilot trial to evaluate safety and biological response - Soratace-1
Medizinische Universität Wien Univ. Klinik f. Innere Med. III, Abt. f. Gastroenterologie/Hepatologie0 个研究点目标入组 20 人开始时间: 2008年4月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •4.1Inclusion criteria
- •-Patients with histologically confirmed HCC not suitable for OLT or resection (>3 nodules, >5 cm diameter, vascular invasion, clinically significant portal hypertension, other contraindications against OLT)
- •-Child-Pugh Stage A or B
- •-Liver disease of any etiology
- •-Written informed consent (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures
- •-Patient must be able to comply with the protocol
- •-Age =18 years
- •-Women of childbearing potential must have a negative serum pregnancy test done 1 week prior to the administration of the Sorafenib.
- •Fertile women and men of childbearing potential (<2 years after last menstruation in women) must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)
- •-Haematology:
- •Absolute neutrophil count (ANC) > 1 x 109/L
- •Platelet count > 40 x 109/L
- •Haemoglobin > 9 g/dL (may be transfused to maintain or exceed this level)
- •Prothrombin time ? 40%
- •-Biochemistry:
- •Total bilirubin ? 5 mg/dL
- •Serum creatinine < 3.0 mg/dL
- •-Life expectancy of >3 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-extrahepatic tumor spread
- •-complete portal vein thrombosis (common trunk)
- •-Child-Pugh-Stage C
- •-Prior TACE or TAE
- •-Other experimental therapies for HCC
- •-Acute variceal bleeding within the last 2 weeks
- •-Large oesophageal varices (>5 mm diameter) without prophylactic band ligation
- •-Past or current history (within the last 2 years prior to randomisation) of malignancies except for the indication under this study and curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix
- •-History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy or history of stroke within < 6 months), excluding hepatic encephalopathy
- •-Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study
- •-Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants for therapeutic purposes
- •-Chronic, daily treatment with aspirin (>325mg/day)
- •-Pregnancy (positive serum pregnancy test) or lactation
- •-Uncontrolled hypertension
- •-Serious, non-healing wound, ulcer, or bone fracture
- •-Currently or recent (within the 30 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study
- •-Clinically significant (i.e. active) cardiovascular disease for example cerebravascular accidents (= 6 months prior to study entry), myocardial infarction (= 6 months prior to study entry), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication
- •-Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of Sorafenib/TACE or patient at high risk from treatment complications
研究者
相似试验
已完成
不适用
The MRS studyCancerTesticular cancerISRCTN56178790Prof. Grzegorz Madej Memorial Foundation Win the health (Fundacja Wygrajmy Zdrowie im Prof. Grzegorza Madeja) (Poland)20
进行中（未招募）
不适用
Sorafenib in the first line treatment of advanced hepatocellular carcinoma with ChildPugh liver function class B. Multicentre phase 3 randomized trial - BOOSTadvanced hepatocellular carcinoma with ChildPugh liver function class BMedDRA version: 9.1Level: LLTClassification code 10024720EUCTR2009-013870-42-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
进行中（未招募）
不适用
Phase II single agent sorafenib in the treatment of relapsed oesophageal/gastric adenocarcinoma in platinum pre-treated patients - Sorafenib upper GI studyEUCTR2008-005062-31-IEICORG, the all-Ireland Co-operative Oncology Research Group54
已完成
2 期
Investigating the role of targeted therapy Sorafenib - the Fms-like tyrosine kinase 3 (FLT3) inhibitor, in combination with intensive chemotherapy, for previously untreated adult patients with Acute Myeloid Leukaemia (AML) with FLT3 mutations. A Phase II randomised placebo-controlled multi-centre studyPreviously untreated adult acute myeloid leukaemia (AML) with FLT3-ITD mutation.Cancer - Leukaemia - Acute leukaemiaACTRN12611001112954eukaemia Foundation of Australia98
招募中
不适用
Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectivenesshepatocellular carcinomaJPRN-UMIN000005847Kyoto university hospital50